Lanreotide (Somatuline Depot)

Somatuline Depot (lanreotide) is covered only for long‑term, non‑oncology treatment of acromegaly (not covered for oncology or other off‑label indications) when patients meet specified initial or continuation criteria. Coverage requires endocrinologist involvement, documentation of acromegaly plus inadequate response to or ineligibility for surgery/radiotherapy (or tumor mass effects), a baseline IGF‑1 above the lab age/gender ULN, adherence to dosing/monitoring (initial 90 mg SC q4w for 3 months; renewals up to 12 months; dose adjustments per prescribing information; extended intervals allowed with GH/IGF‑1 testing 6 weeks after interval changes) and supporting clinical/lab records.

"FDA‑approved non-oncology indication: long-term treatment of acromegalic individuals who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy."